Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a prospective Phase 2 study, 48 patients with resected pancreatic ductal adenocarcinoma were treated with erlotinib (100 mg daily) and capecitabine (800 mg/m2 twice daily Monday-Friday) concurrently with intensity-modulated radiation therapy followed by four cycles of adjuvant gemcitabine (1000 mg/m2 on days 1, 8, and 15 every 28 days) and erlotinib (100 mg daily).

Phase 2 Study of Erlotinib Combined with Adjuvant Chemoradiation and Chemotherapy in Patients with Resectable Pancreatic Cancer